Ventral Tegmental Area Afferents and Drug-Dependent Behaviors

Idaira Oliva and Matthew J. Wanat*

Department of Biology, Neurosciences Institute, University of Texas at San Antonio, San Antonio, TX, USA

Drug-related behaviors in both humans and rodents are commonly thought to arise from aberrant learning processes. Preclinical studies demonstrate that the acquisition and expression of many drug-dependent behaviors involves the ventral tegmental area (VTA), a midbrain structure comprised of dopamine, GABA, and glutamate neurons. Drug experience alters the excitatory and inhibitory synaptic input onto VTA dopamine neurons, suggesting a critical role for VTA afferents in mediating the effects of drugs. In this review, we present evidence implicating the VTA in drug-related behaviors, highlight the diversity of neuronal populations in the VTA, and discuss the behavioral effects of selectively manipulating VTA afferents. Future experiments are needed to determine which VTA afferents and what neuronal populations in the VTA mediate specific drug-dependent behaviors. Further studies are also necessary for identifying the afferent-specific synaptic alterations onto dopamine and non-dopamine neurons in the VTA following drug administration. The identification of neural circuits and adaptations involved with drug-dependent behaviors can highlight potential neural targets for pharmacological and deep brain stimulation interventions to treat substance abuse disorders.

Keywords: VTA, substance use disorders, addiction, dopamine, plasticity

INTRODUCTION

Illicit drug use is a significant global problem, with the United Nations Office on Drugs and Crime estimating that 246 million people worldwide used illicit drugs in 2013. More problematic is the high incidence of substance use disorders (SUDs), which in 2014 was estimated to afflict roughly 21.5 million people in the US, corresponding to ~8% of the population (1). In addition to the personal impact of a SUD, there is a significant economic impact due to lost productivity, crime, and health care costs, which according to the US office of National Drug Policy is estimated to cost $180.8 billion per year in the US alone.

SUDs are now recognized to exist along a continuum where the severity of the disorder is related to the number of diagnostic criteria met by an individual within the past year. According to the DSM-V, the criteria for a SUD fall into four major symptomatic clusters: impaired control (i.e., use more than intended), social impairment (i.e., substance use at the expense of personal relationships and impaired job performance), risky behavior (i.e., use despite known adverse consequences), and pharmacological effects (i.e., tolerance and withdrawal). One of the most daunting aspects in treating SUDs is the high incidence of relapse, which occurs in ~40–60% of individuals (2). In drug users, exposure to drug-paired cues elicits craving that in turn can promote the possibility of a relapsing episode (3). Weakening the relationship between drugs and associated cues holds promise as a non-pharmacological method for treating SUDs (4). However, our understanding of
the specific neural circuits and neural adaptations responsible for drug-related behaviors is incomplete.

**RODENT MODELS OF DRUG-DEPENDENT BEHAVIORS**

Rodent model systems are commonly employed to examine the effects of abused drugs on behavior. In this review, we will concentrate on psychostimulants and opiates, as extensive laboratory research has focused on these drug categories. The non-contingent administration of psychostimulants or opiates increases locomotor activity in rodents (5). Repeated non-contingent drug injections can lead to a progressive and long-lasting increase in this drug-induced locomotor activity, a phenomenon referred to as behavioral sensitization (5). A single injection of cocaine at high doses is also capable of eliciting sensitization (6, 7). Furthermore, even when no drug is administered, locomotor activity is elevated in the same context where animals received a single drug injection on the preceding day (8). These results illustrate that the association between a drug and the context where the drug is experienced is rapidly learned following a single exposure.

Drug-paired cues exert a powerful influence over behavioral actions in individuals with a SUD (3). The development of an association between drugs and cues can be examined in humans in the laboratory (9, 10), as well as in rodents by utilizing a conditioned place preference (CPP) behavioral paradigm (11). This rodent assay involves repeated non-contingent drug injections in one chamber and control injections in an adjacent, but contextually distinct chamber. The relative preference between the drug-paired and control contexts is subsequently assessed in a test session where the rodent can freely access both chambers in a drug-free state (11). The CPP training procedure can include an extinction phase and a reactivation test (12, 13), which models drug abstinence and relapse observed in humans suffering from a SUD. While CPP paradigms examine contextual learning involving reinforcing outcomes, conditioned place aversion (CPA) assays examine learning involving aversive outcomes. In particular, CPA paradigms are commonly utilized to study the negative affective state following drug withdrawal (14, 15).

Behavioral sensitization and CPP paradigms are relatively easy to implement, but they require experimenter administered drug injections. Rodents can be readily trained to self-administer drugs via an intravenous catheter. A number of drug self-administration assays have been developed to model the behavioral symptoms observed in humans with a SUD. For example, rodents with limited access (1 h) to drugs in daily self-administration sessions maintain stable drug intake. However, rodents with extended access (6 h) to drugs increase their intake over multiple training sessions, similar to the escalated drug consumption that can be observed in individuals diagnosed with a SUD (16–18). Just as drug use does not necessarily lead to a SUD, not every rodent who self-administers drugs will develop an addiction-related phenotype. When rodents are extensively trained to self-administer drugs (~3 months), a subset of rats exhibit characteristics found in humans with SUDs, such as persistent drug seeking in the absence of reinforcement, exerting greater effort to obtain a drug infusion, and seeking drugs despite aversive consequences (19). Rodents trained to self-administer drugs are also used to model relapse. Relapse in humans is often precipitated by three major factors: taking the drug, exposure to cues previously associated with the drug, or experiencing a stressful life-event (20–22). These same triggers (drug intake, exposure to drug-related cues, or stress) can reinduce drug-seeking behaviors in rodent drug self-administration models as well (23).

Just as with humans with a SUD, drug-dependent behaviors in rodents involve a component of learning, whether it is contextual (behavioral sensitization, CPP, CPA, and cue-induced reinstatement) or operant (drug self-administration). While numerous brain regions are involved with mediating learning and drug-related behaviors, we will focus on the ventral tegmental area (VTA) in this review. We will also discuss the major inputs to the VTA, how these inputs influence VTA neuron activity, and present recent findings on how these VTA afferents are involved with drug-dependent behaviors.

**VTA INVOLVEMENT IN DRUG-DEPENDENT BEHAVIORS**

The dopamine neurons arising from the VTA that project to the nucleus accumbens (NAc) are involved with mediating the reinforcing actions of abused substances (24–26). While abused drugs increase dopamine levels in the NAc (27, 28), many non-habit forming drugs do not affect dopamine overflow (27). Psychostimulants affect dopamine levels primarily by altering dopamine clearance from the extracellular space (29, 30), whereas opiates indirectly elevate dopamine transmission by suppressing inhibitory input onto dopamine neurons (31–33).

The neural circuitry mediating any behavior is complex, though extensive research over the past few decades illustrates that the VTA is critically involved with both rewarding and aversive drug-dependent behaviors. For example, the VTA is required for behavioral sensitization induced by amphetamine or mu-opioid receptor agonists, though evidence for the involvement of the VTA in cocaine behavioral sensitization is mixed (5). The VTA is also involved with CPP for both psychostimulants and opiates (34–39), and with CPA elicited by kappa opioid receptor activation (15). The VTA is also necessary for stress-, cue-, and drug-primed reinstatement in rodents self-administering cocaine (23, 40–42) or heroin (43–45). While VTA-dependent behaviors are often mediated by dopamine neurons, increasing evidence illustrates the involvement of non-dopamine VTA neurons in regulating behavioral outcomes.

**DIVERSE NEURONAL POPULATIONS WITHIN THE VTA**

The VTA along with the neighboring substantia nigra pars compacta are the primary dopamine producing nuclei in the brain (46). Early electrophysiological recordings indicated that the VTA was comprised of two distinct neuronal populations, presumed to be dopamine neurons and local GABA interneurons (31, 47). However, a subset of VTA neurons exhibited a unique
electrophysiological response to serotonin and opioid receptor agonists, providing evidence for the existence of an additional neuronal population in the VTA (48). Accumulating evidence over the past decade has highlighted the complexity of the VTA both in regards to neuronal composition and projection targets.

Dopamine neurons comprise the largest neuronal population within the VTA, as tyrosine hydroxylase (TH), the rate-limiting enzyme for dopamine synthesis, is found in ~60% of VTA neurons (46, 49). VTA dopamine neurons typically innervate only a single target region, with different populations projecting to numerous brain nuclei, including the NAc, dorsal striatum, cortex, amygdala, globus pallidus, and lateral habenula (LHb) (46, 50, 51). However, recent evidence indicates that dopamine neurons projecting to the medial NAc also send collaterals outside of the striatum (50).

Traditionally, dopamine neurons have also been identified based upon electrophysiological properties, including the presence of a long triphasic action potential, a low baseline firing rate, burst firing, and the presence of the Ih current (52, 53). However, action potential duration may not be sufficient to identify the neurotransmitter content of VTA neurons (49, 54). Additionally, many neurons within the medial aspects of the VTA have Ih but do not contain TH. While action potential duration and Ih are not always indicative of dopamine content, these electrophysiological properties can be related to where VTA neurons project (55–57).

The second largest neuronal population in the VTA consists of GABA neurons (~25%) that are commonly identified by the presence of glutamic acid decarboxylase (GAD) (58, 59). While initially thought to function primarily as local interneurons (31), VTA GABA neurons directly influence the activity of VTA dopamine neurons (60, 61) and also project to the ventral pallidum (VP), lateral hypothalamus (LH), and LHb, with smaller projections to the amygdala, prefrontal cortex (PFC), and NAc (62–64). Recently, dopamine neurons were identified as an additional source of GABA in the VTA, as these neurons can synthesize GABA through an aldehyde dehydrogenase-mediated pathway (65). VTA and substantia nigra dopamine neurons package GABA into vesicles through the vesicular transporter for dopamine, indicating that GABA can be coreleased with dopamine to elicit electrophysiological effects on medium spiny neurons in both the NAc and dorsal striatum (66, 67).

In addition to dopamine and GABA neurons, a small percentage of VTA neurons contain vesicular glutamate transporter 2 (VGluT2), a marker for glutamate neurons. These neurons predominantly reside in the medial aspects of the VTA and project to the ventral striatum, PFC, VP, amygdala, and LHb, as well as synapse onto local dopamine neurons (57, 64, 68–72). A subset of the VGluT2 positive neurons in the VTA also express TH and can project to the PFC and ventral striatum (70). These neurons release both dopamine and glutamate (73–77) though they are not typically released at the same site or from the same synaptic vesicles (78). While the VTA was thought to be comprised solely of dopamine and GABA neurons, recent studies illustrate that the VTA is comprised of dopamine neurons that can corelease GABA, dopamine neurons that corelease glutamate, GABA neurons, and glutamate neurons.

Optogenetic modulation of VTA neurons can elicit either appetitive or aversive behavioral outcomes depending upon the neuronal population that is targeted. Activation of dopamine neurons is acutely reinforcing and sufficient for establishing a CPP, whereas silencing dopamine neurons is aversive and elicits a CPA (60, 79, 80). Stimulating VTA dopamine neurons also enhances reinforcing behaviors in operant tasks (81–84). In contrast, selective activation of VTA GABA neurons is aversive, elicits a CPA, and reduces reward consumption by inhibiting the activity of local VTA dopamine neurons (60, 61). Interestingly, activating VTA GABA neurons that synapse onto cholinergic interneurons in the NAc enhances the discrimination between neutral and aversive stimuli (63). Optogenetic activation of VGluT2-containing neurons in the VTA is also sufficient for establishing CPP, an effect that is mediated by activating local VTA dopamine neurons (72). Collectively, these studies suggest that VTA-mediated behavioral effects, including drug-dependent behaviors, likely involve a complex interplay between the distinct neuronal populations in the VTA.

Afferent Regulation of the VTA

The VTA is innervated by a diverse array of inputs, many of which are interconnected. Large afferents to the VTA include the rostromedial tegmental nucleus (RMTg), VP, bed nucleus of the stria terminalis (BNST), LH, pedunculopontine tegmental nucleus (PPT), laterodorsal tegmental nucleus (LDT), dorsal raphe nucleus (DR), NAc, PFC, and amygdala (50, 85–87). While VTA dopamine and GABA neurons are innervated by many of the same brain regions (50), little is known about the inputs to VGluT2 positive neurons in the VTA. Below, we will discuss how notable inputs to the VTA can influence the activity of VTA neurons, how these inputs influence VTA-dependent behaviors, and recent findings on VTA afferents involved with drug-dependent behaviors.

Rostromedial Tegmental Nucleus

The RMTg (also referred to as the tail of the VTA) is a nucleus comprised of GABA neurons that function as an inhibitory relay between the LHb and the VTA (86, 88–92). Lesions of the RMTg demonstrate a critical role for this brain region in modulating aversive behaviors (86). Additionally, neurons in the RMTg are activated by aversive stimuli and inhibited by rewards (86). The RMTg heavily influences the firing of VTA neurons, as RMTg inactivation increases dopamine neuron firing (93), whereas stimulating the RMTg attenuates dopamine neuron firing (93–95).

The RMTg is increasingly recognized as an important nucleus in mediating the effects of abused drugs. The reinforcing effect of opiates was originally thought to arise from activation of mu-opioid receptors on VTA GABA interneurons (31), though accumulating evidence suggests the major target of opiates is instead the RMTg afferents to the VTA (33, 96, 97). The administration of morphine decreases RMTg cell firing, which reduces the inhibition onto VTA dopamine neurons, resulting in elevated dopamine neuron firing (94–96). Indeed, selective activation of mu-opioid receptors in RMTg neurons projecting to the VTA is sufficient for eliciting a real-time place preference (98). Following opiate withdrawal, inhibiting RMTg neurons no longer elevates VTA dopamine neuron firing. This inability of the RMTg to
and activation of these neurons elicits aversive and anxiogenic behaviors (128–130). Interestingly, glutamatergic neurons disinhibiting VTA GABA neurons, resulting in anxiolytic behavior in rats self-administering cocaine (101). The RMTg is also necessary for cocaine-related aversive behaviors that are observed once the rewarding effect of cocaine dissipates (102). Further experimentation is needed to validate whether the RMTg projection to the VTA is involved with both aversive and reinforcing behaviors elicited by cocaine.

Ventral Pallidum

The VP is involved in processing rewarding stimuli and motivated behaviors (103). GABA neurons in the VP provide a large source of inhibitory input to the VTA (87, 104). Activating VP neuron terminals elicits inhibitory GABA currents in both dopamine and non-dopamine VTA neurons (105). The functional effect of inactivating the VP results in an increase in the population activity in putative dopamine neurons (106) though the effect on non-dopamine VTA neurons is unknown. Numerous lines of evidence implicate the VP in drug-dependent behaviors. VP neurons projecting onto dopamine and non-dopamine neurons are acutely inhibited by opiates (105). Additionally, VP lesions or pharmacological manipulations in the VP can block morphine-induced sensitization (107, 108), drug-induced CPP (35, 109, 110), self-administration (111), and reinstatement (40, 41, 112). VP neurons projecting to the VTA are Fos activated following cue-induced reinstatement for cocaine (101) and silencing these neurons is sufficient for blocking cue-induced reinstatement (113). While VP neurons project to both dopamine and non-dopamine neurons in the VTA (105), it is unclear what neuronal population(s) in the VTA are influenced by the VP inputs during drug-dependent behaviors.

Bed Nucleus of the Stria Terminalis

The BNST is involved in mediating fear and anxiety (114–120) and is considered to be a relay nucleus between stress and reward pathways (121, 122). The neuronal composition of the BNST is diverse, with efferent populations of GABA and glutamate neurons along with local GABA and cholinergic interneurons (122, 123). BNST neurons also express an assortment of neuropeptides including neuropeptide Y, corticotropin-releasing factor, enkephalin, dynorphin, and substance P (124). Electrical stimulation of the BNST exerts an excitatory influence on midbrain dopamine neurons (122, 125, 126) and elevates dopamine release in the NAc (127). Recent studies suggest that this excitatory effect on dopamine neurons is predominately mediated through GABA BNST neurons disinhibiting VTA GABA neurons, resulting in anxiolytic and rewarding behavioral outcomes (128–130). Interestingly, glutamate neurons in the BNST also innervate VTA GABA neurons, and activation of these neurons elicits aversive and anxiogenic behaviors (129). Within the context of drug-dependent behaviors, local pharmacological manipulations illustrate a critical role of the BNST in the stress-induced reinstatement of drug seeking (41, 131, 132). Furthermore, recent studies implicate the BNST–VTA pathway in the locomotor-activating effects of cocaine (133) and in the expression of cocaine CPP (134), though the involvement of this pathway in other drug-dependent behaviors has not yet been explored.

Lateral Hypothalamus

The LH is critical for the expression of motivated behaviors including feeding and drug seeking (135). The LH provides both glutamate and GABA inputs to the VTA (85, 136). In addition, LH neurons projecting to the VTA also contain neuropeptides such as neuropeptide, orexin/hypocretin (137, 138). Electrical stimulation of the LH increases the activity of putative dopamine neurons and inhibits the activity of putative GABA neurons in the VTA (139). Many lines of evidence demonstrate that activation of this LH–VTA pathway is reinforcing. Rodents will readily self-stimulate for electrical activation of the LH, but this behavioral effect is inhibited by dopamine receptor antagonism (140) or inactivation of the VTA (141). Furthermore, optogenetic activation of LH inputs to the VTA also supports self-stimulation through a neuropeptide-dependent mechanism (142).

Accumulating evidence over the past decade highlights the importance of orexin-containing neurons in feeding, the sleep/wake cycle, and drug-dependent behaviors (143). Orexin-producing neurons are exclusively localized within the hypothalamus and project widely throughout the brain (144), though it is the projection to the VTA that is heavily involved with drug-dependent behaviors. Intra-VTA injections of orexin receptor antagonists attenuate morphine CPP (145, 146), which is consistent with the reduced morphine dependence observed in orexin-deficient mice (147). Conversely, intra-VTA administration of orexin reinstates morphine CPP (12). Orexin antagonists targeting the VTA also diminish behavioral sensitization to cocaine (148), cocaine self-administration (149), and cue-induced reinstatement (150). Interestingly, orexin neurons in the LH also contain dynorphin, which inhibits the activity of VTA dopamine neurons. A recent study suggests that orexin in the VTA facilitates drug-related behaviors in part through attenuating the effects of dynorphin (149). Although the orexin-containing neurons in the LH have received considerable attention in the context of addiction, additional neuronal populations in the LH–VTA pathway are also likely involved in drug-dependent behaviors, as the non-orexin-producing neurons in the LH are Fos activated following cue-induced reinstatement (101).

Laterodorsal Tegmental Nucleus and Pedunculopontine Tegmental Nucleus

The LDT and PPT are involved in modulating arousal and reward-driven behaviors (92, 151–154). These nuclei are comprised of distinct populations of acetylcholine, GABA, and glutamate neurons that project to the midbrain dopamine system (155, 156). Anatomical studies indicate that the VTA primarily receives input from the LDT (87, 155, 157). In vivo electrophysiological
experiments illustrate that electrical stimulation of the LDT elicits burst firing in putative VTA dopamine neurons (158). Selective activation of LDT inputs to the VTA evokes excitatory currents in VTA dopamine neurons projecting to the lateral NAc (92). Stimulating this LDT–VTA pathway in vivo elicits CPP and reinforces operant responding (92, 154). Increasing evidence indicates that the LDT is also involved in drug-dependent behaviors. Specifically, local pharmacological manipulations demonstrate the LDT is critical for the acquisition and expression of cocaine CPP (159), as well as with cocaine-primed reinstatement of drug seeking (160). Interestingly, the cholinergic neurons of the LDT are involved with the behavioral responsiveness to cocaine-paired cues (161). Further studies are needed to ascertain whether drug-dependent behaviors also involve the GABA and glutamate projections from the LDT to the VTA.

Whereas the VTA is preferentially innervated by the LDT, the PPT primarily targets the substantia nigra (87, 155). Although the anatomical evidence indicates there is a small PPT projection to the VTA (87, 155), electrophysiological studies in vivo and in vitro suggest a functional relationship exists between the PPT and VTA (106, 162, 163). The discrepancy between the anatomical and electrophysiological studies is unclear, though proposed explanations include the possibility that a single PPT neuron innervates numerous VTA neurons or that electrical stimulation excites fibers of passage or nearby regions, such as the LDT (87). Regardless, electrical stimulations targeting the PPT increases burst firing of putative VTA dopamine neurons (106), while PPT inactivation reduces dopamine neuron firing to salient stimuli (162). The PPT is also implicated in drug-dependent behaviors, as lesions attenuate amphetamine- and morphine-induced locomotor activity (164), and PPT inactivation reduces cocaine-primed reinstatement of drug seeking (160). PPT lesions reduce both heroin self-administration and morphine CPP (165, 166). However, PPT cholinergic neurons are not involved with cocaine self-administration, heroin self-administration, cocaine CPP, and heroin CPP (167), suggesting the involvement of PPT glutamate and/or GABA neurons in these drug-related behaviors.

**Dorsal Raphe**

The DR is the primary source of serotonin in the brain, but also contains glutamate (85), GABA (168), and dopamine neurons (169). While the DR is often studied within the context of controlling affective state (170), it is also involved in reinforcing instrumental behavior (171). Serotonin exerts a variety of electrophysiological responses in VTA neurons. The predominant in vitro response in putative dopamine neurons is excitatory, though a small proportion of dopamine neurons are inhibited by serotonin (172). In contrast, equal numbers of putative GABA neurons are excited and inhibited by serotonin (172). The net effect of these electrophysiological responses appears to be excitatory, as in vivo intra-VTA administration of serotonin elevates dopamine levels in the NAc (173).

Serotonin influences drug-related behaviors (174), which could involve the DR serotonin neurons projecting to the VTA. However, the DR projection to the VTA is primarily comprised of glutamate neurons that predominantly innervate dopamine neurons (85, 87, 175). Activation of DR glutamate neurons evokes excitatory currents in VTA dopamine neurons and elicits dopamine release in the NAc (175). Selective activation of the non-serotonergic DR–VTA pathway reinforces instrumental behavior and is sufficient for eliciting CPP (175, 176). In contrast, activation of serotonergic DR neurons projecting to the VTA is only weakly reinforcing (176). These anatomical and behavioral findings suggest that the VTA is likely not a primary locus where serotonin acts to influence drug-related behaviors. Instead, the non-serotonergic DR neurons projecting to the VTA are well positioned to mediate drug-dependent behaviors, though this has not yet been experimentally examined.

**Nucleus Accumbens**

GABA neurons in the NAc project to the VTA and are thought to mediate a “long-loop” inhibitory feedback to regulate dopamine neuron activity (177). Mu-opioid receptor agonists acutely inhibit the GABA afferents from the NAc to the VTA (33, 178). The inhibitory transmission from the NAc inputs onto VTA GABA neurons is enhanced following repeated injections of cocaine, which in turn disinhibits VTA dopamine neurons (179). In addition to being influenced by opiates and psychostimulants, the NAc afferents to the VTA are Fos activated during cocaine cue-induced reinstatement (101). While these results suggest the NAc–VTA pathway is involved in drug-related behaviors, no experiments to date have examined the behavioral effect of selectively perturbing this pathway.

**Prefrontal Cortex**

The medial PFC mediates a variety of cognitive functions (180), is involved in the reinstatement of drug-seeking behavior (23), and exhibits Fos activation following an acute administration of amphetamine (181). The VTA receives a dense glutamate projection from the medial PFC (85), with pyramidal neurons synapsing onto both dopamine and non-dopamine VTA neurons (62, 182). Electrically stimulating the PFC can either inhibit or excite putative dopamine neurons within the VTA (183, 184). Whereas single pulse or low frequency PFC stimulation inhibits a majority of VTA dopamine neurons (183–185), burst stimulation of the PFC excites >90% of VTA dopamine neurons (184). The mechanism behind the dopamine neuron excitation is unclear, as VTA dopamine neurons receive sparse input from the PFC (87, 186), with <15% of VTA dopamine neurons being excited by selective activation of medial PFC inputs (50). These findings collectively suggest the medial PFC preferentially targets VTA GABA neurons, though the relevance of this PFC-VTA pathway in drug-dependent behaviors has not been examined.

**Amygdala**

The amygdala is an interconnected group of nuclei involved with attributing emotional value to cues (187, 188). The VTA receives amygdala input arising from the central nucleus of the amygdala (CeA) subdivision (87, 189). The CeA contains predominantly GABA neurons and is involved with fear conditioning (187, 188, 190), as well as with mediating the general motivational influence...
of rewarding cues (191, 192). In the context of drug-dependent behaviors, the CeA facilitates the expression of conditioned responding (193) and is also involved with mediating stress-induced reinstatement of drug-seeking behavior (194, 195). While the CeA projects to the VTA, it is currently unknown how this pathway influences VTA neuron activity and whether it is crucial for drug-dependent behaviors.

**DRUG-INDUCED SYNAPTIC PLASTICITY ON VTA NEURONS**

The transition of an individual from drug naive or casual drug user to SUDs involves changes in the function of specific neural circuits (196). Given the importance of the VTA in drug-related behaviors, the synaptic adaptations in VTA dopamine neurons have been extensively studied and reviewed elsewhere (197–201). Numerous studies from a variety of laboratories have consistently demonstrated an increase in excitatory synaptic strength onto VTA dopamine neurons after *in vivo* exposure to abused drugs (202–208). Many of these studies examined the effect of drugs on the ratio of the AMPA receptor current to the NMDA receptor current (AMPA/NMDA) in VTA neurons, which allows for comparing the excitatory synaptic strength between different groups of animals (i.e., drug treated vs. control). *In vivo* exposure to drugs of abuse increases the AMPA/NMDA (202–204, 206, 207), which is mediated by insertion of calcium-permeable AMPA receptors and removal of NMDA receptors in VTA dopamine neurons (205, 208).

In addition to the excitatory synaptic alterations in VTA dopamine neurons, *in vivo* exposure to drugs also modulates inhibitory synaptic inputs to the VTA. For example, repeated injections of cocaine potentiate the NAc inhibitory input to VTA GABA neurons, which results in a disinhibition of dopamine neurons (179). This disinhibition also facilitates the ability to elicit excitatory long-term potentiation (LTP) in VTA dopamine neurons (209). VTA dopamine neurons are also capable of undergoing inhibitory LTP. Furthermore, this inhibitory LTP is blocked following an *in vivo* exposure to opiates (210, 211). A myriad of drug-induced synaptic alterations have been reported, though it is important to note that the full complement of electrophysiological changes and the duration of these alterations in VTA neurons depends upon the drug, the dose, and the manner the drug is administered (202–204, 206, 207, 212). Few studies to date have examined whether these drug-induced synaptic changes occur in an afferent-specific manner (179, 212). Indeed, *in vivo* exposure to different classes of abused drugs results in alterations in distinct excitatory inputs to VTA dopamine neurons (212). Although much has been learned regarding synaptic alterations in the VTA following non-contingent injections of abused drugs, additional studies are needed to ascertain the similarities and differences in the synaptic changes evoked by different classes of abused drugs (psychostimulants, opiates, alcohol, nicotine, etc.). Furthermore, electrophysiological studies are also needed to identify which VTA afferents and what VTA neuronal populations undergo synaptic alterations following contingent drug self-administration.

**CONCLUSION**

The high incidence of relapse illustrates the need for identifying new therapeutic approaches for the treatment of SUDs. The treatment of opioid dependence is complicated by the severe withdrawal symptoms experienced by individuals when ceasing drug intake. The current treatment options for opioid SUDs typically focus on opioid maintenance with methadone or buprenorphine and detoxification with alpha-2 receptor agonists. However, these current treatment options often result in relapse (213). Currently there is no FDA-approved pharmacotherapy for the treatment of cocaine SUDs, though N-acetylcysteine is a promising and well-tolerated drug that reduces cocaine-seeking in rodents and craving in cocaine-dependent humans (214–217). Over the past decade, research on effective pharmacological treatments for alcohol SUDs has identified many potential targets, including opioid receptors (218), dopamine receptors (219), glutamate receptors (220), GABA receptors (221), and adrenergic receptors (222). Preclinical research highlighted the cannabinoid system as a promising target for multiple SUDs (223, 224). However, a cardiovascular clinical study examining the efficacy of rimanabant, a cannabinoid receptor antagonist, elicited severe negative neuropsychiatric effects (225) and has dampened enthusiasm for targeting the endocannabinoid system for treating SUDs. Unfortunately, no single pharmacotherapy currently exists for treating a broad spectrum of SUDs.

An alternative therapeutic direction for the treatment of SUDs involves the use of deep brain stimulation (DBS), which commonly has been utilized for the treatment of movement disorders. In preclinical studies, DBS targeting the NAc reduced cocaine behavioral sensitization (226), morphine CPP (227), reinstatement of heroin-seeking (228), and reinstatement of cocaine-seeking (229–231). Additionally, DBS targeting the LHb reduces cocaine self-administration and the reinstatement of cocaine-seeking (232). Consistent with the rodent DBS experiments, clinical studies indicate a complete remission or prolonged cessation of heroin use after DBS in the NAc in humans (233, 234). A considerable drawback of implementing DBS in humans is the invasive nature of implanting the probe. However, a couple of recent reports illustrate that non-invasive transcranial magnetic stimulation of the PFC is effective at reducing drug use and craving (235, 236). While there are promising new therapeutic approaches for treating SUDs, the ultimate goal for any intervention is to be effective and as specific as possible to limit side effects. Thus, additional basic science research is needed for identifying the specific neural circuits and adaptations responsible for the development of drug-dependent behaviors.

The implementation of optogenetic and chemogenetic approaches in behavioral experiments has validated and identified specific neural circuits that mediate a range of appetitive and aversive behaviors. Many of these studies manipulated brain regions implicated in SUDs (237), though relatively few have modulated neural circuits within the context of drug-dependent behaviors (98, 113, 133). While activity within the VTA is central to numerous drug-dependent behaviors, many questions remain. Future experiments are needed to (i) determine which
VTA afferents and what neuronal populations in the VTA mediate a particular drug-dependent behavior and (ii) elucidate the associated afferent-specific synaptic changes on both dopamine and non-dopamine neurons within the VTA. Identifying the neural circuits and adaptations responsible for drug-dependent behaviors in rodents can highlight specific neural circuits for targeted pharmacological and DBS therapeutic interventions to treat humans suffering from a SUD.

REFERENCES

1. Center for Behavioral Health Statistics and Quality. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. (HHS Publication No. SMA 15-4927, NSDUH Series H-50) (2015).
2. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA (2000) 284:1689–95. doi:10.1001/jama.284.13.1689
3. O'Brien CP, Childress AR, Ehrman R, Robbins SJ. Conditioning factors in drug abuse: can they explain compulsion? J Psychopharmacol (1998) 12:15–22. doi:10.1177/02698811980120103
4. Xue YX, Luo YX, Wu P, Shi HS, Xue LF, Chen C, et al. A memory retrieval-extinction procedure to prevent drug craving and relapse. Science (2012) 336:241–5. doi:10.1126/science.1215070
5. Vanderschuren LJ, Kalivas PW. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) (2000) 151:99–120. doi:10.1007/s002130000493
6. Jackson HC, Nutt DJ. A single preexposure produces sensitization to the locomotor effects of cocaine in mice. Pharmacol Biochem Behav (1993) 45:233–5. doi:10.1016/0091-3057(93)90533-Y
7. Wanat MJ, Sparta DR, Hufp FW, Bowers MS, Melis M, Bonci A. Strain specific synaptic modifications on ventral tegmental area dopamine neurons after ethanol exposure. Biol Psychiatry (2009) 65:646–53. doi:10.1016/j.biopsych.2008.10.042
8. Dong Y, Sael D, Thomas M, Faust R, Bonci A, Robinson T, et al. Cocaine-induced potentiation of synaptic strength in dopamine neurons: behavioral correlates in GluRa(-/-) mice. Proc Natl Acad Sci U S A (2004) 101:14282–7. doi:10.1073/pnas.0401553101
9. Mayo LM, Fraser D, Childs E, Momenan R, Hommer DW, de Wit H, et al. Conditioned preference to a methamphetamine-associated contextual cue in humans. Neuropsychopharmacology (2013) 38:921–9. doi:10.1038/npp.2013.33
10. Mayo LM, de Wit H. Acquisition of responses to a methamphetamine-associated cue in healthy humans: self-report, behavioral, and psychophysiological measures. Neuropsychopharmacology (2015) 40:1734–41. doi:10.1038/npp.2015.21
11. Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol (1998) 56:613–72. doi:10.1016/S0079-6183(98)00060-4
12. Harris GC, Wimmer M, Ashton-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature (2005) 437:556–9. doi:10.1038/nature04071
13. Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land RB, et al. Selective p38alpha MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron (2011) 71:498–511. doi:10.1016/j.neuron.2011.06.011
14. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther (1993) 264:489–95.
15. Chefer VI, Backman CM, Gigante ED, Shippenberg TS. Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion. Neuropsychopharmacology (2013) 38:2623–31. doi:10.1038/npp.2013.171
16. Ahmed SH, Koob GF. Transition from moderate to excessive drug intake: change in hedonic set point. Science (1998) 282:298–300. doi:10.1126/science.282.5387.298

AUTHOR CONTRIBUTIONS

MW and IO contributed to the writing of this review article.

FUNDING

This work was supported by National Institutes of Health Grant DA033386 (MW).

17. Ahmed SH, Koob GF. Long-lasting increase in the set point for cocaine self-administration after escalation in rats. Psychopharmacology (Berl) (1999) 146:303–12. doi:10.1007/s00210051121
18. Ahmed SH, Walker JR, Koob GF. Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology (2000) 22:413–21. doi:10.1007/s0893-133X(99)00133-5
19. Deroche-Gamonet V, Belin D, Piazza PV. Evidence for addiction-like behavior in the rat. Science (2004) 305:1014–7. doi:10.1126/science.1099020
20. Jaffé JH, Cascella NG, Kumar KM, Sherer MA. Cocaine-induced cocaine craving. Psychopharmacology (Berl) (1989) 97:59–64. doi:10.1007/BF00434141
21. Carter BL, Tiffany ST. Meta-analysis of cue-reactivity in addiction research. Addiction (1999) 94:327–40. doi:10.1046/j.1360-0443.1999.943327.x
22. Sinha R. How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berl) (2001) 158:343–59. doi:10.1007/s0021300109917
23. Kalivas PW, McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl) (2003) 168:44–56. doi:10.1007/s00213-003-1393-2
24. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci (2005) 8:1445–9. doi:10.1038/nn1578
25. Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res (2008) 14:169–83. doi:10.1007/BF03033808
26. Wanat MJ, Willuhn I, Clark JJ, Phillips PE. Phasic dopamine release in appetitive behaviors and drug addiction. Curr Drug Abuse Rev (2009) 2:195–213. doi:10.2174/1874473710902020195
27. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A (1988) 85:5274–8. doi:10.1073/pnas.85.14.5274
28. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu opioid receptor mechanism. Science (1997) 276:2048–50. doi:10.1126/science.276.5321.2048
29. Kuhn WG, Ewing AG, Near JA, Wightman RM. Amphetamine attenuates the stimulated release of dopamine in vivo. J Pharmacol Exp Ther (1985) 232:88–94.
30. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (1987) 237:1219–23. doi:10.1126/science.2820058
31. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci (1992) 12:843–8.
32. Melis M, Gessa GL, Diana M. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry (2000) 24:993–1006. doi:10.1016/S0278-5846(00)00119-6
33. Matsui A, Jarvis BC, Robinson BG, Hentges ST, Williams JT. Separate GABA and dopamine mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behav Brain Res (1999) 101:129–52. doi:10.1016/S0166-4328(99)00022-4
37. Wang B, Luo F, Ge XC, Fu AH, Han JS. Effects of lesions of various brain areas on drug priming or footshock-induced reactivation of extinguished conditioned place preference. Brain Res (2002) 950:1–9. doi:10.1016/ s0006-8993(02)02980-3

38. Harris GC, Aston-Jones G. Critical role for ventral tegmental glutamate in preference for a cocaine-conditioned environment. Neuropsychopharmacology (2003) 28:73–6. doi:10.1016/s0893-1339(03)00311-0

39. Sticht M, Mitsuba J, Tucci M, Leri F. Reacquisition of heroin and cocaine place preference involves a memory consolidation process sensitive to systemic and intra-ventral tegmental area naloxone. Neurobiol Learn Mem (2010) 93:248–60. doi:10.1016/j.nlm.2009.10.005

40. McFarland K, Kalivas PW. The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. J Neurosci (2001) 21:8655–63.

41. McFarland K, Davidse SB, Lapish CC, Kalivas PW. Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci (2004) 24:1551–60. doi:10.1523/JNEUROSCI.3207-04.2004

42. Mahler SV, Smith RJ, Aston-Jones G. Interactions between VTA orexin and glutamate in cued reinstatement of cocaine seeking in rats. Psychopharmacology (Berlin) (2013) 226:687–98. doi:10.1007/s00213-012-2681-5

43. Stewart J. Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebroventricular application of morphine in the ventral tegmental area. Pharmacol Biochem Behav (1984) 20:917–23. doi:10.1016/0301-0536(84)90117-0

44. Bossert JM, Liu SY, Lu L, Shaham Y. A role of ventral tegmental area dopamine neurons recorded immunocytochemically identified rat dopamine neurons recorded electrophysiologically. J Physiol (1992) 450:455–68. doi:10.1113/jphysiol.1992.sp019136

45. Cameron DL, Wessendorf MW, Williams JT. A subset of ventral tegmental area neurons is inhibited by dopamine, 5-hydroxytryptamine and opioids. Neuroscience (1997) 77:153–66. doi:10.1016/S0306-4522(96)00444-7

46. Margolis EB, Lock H, Hjelmstad GO, Fields HL. The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons? J Physiol (2006) 577:907–24. doi:10.1113/jphysiol.2006.117069

47. Beier KT, Steinberg EE, Deloach KE, Xie S, Miyamichi K, Schwarz L, et al. Circuit architecture of VTA dopamine neurons revealed by systemic a combined fluorescent retrograde tracer and immunofluorescence study in the rat. J Comp Neurol (2004) 473:222–37. doi:10.1002/cne.20097

48. Chuhma N, Zhang H, Masson J, Zhuang X, Sulzer D, Hen R, et al. Dopamine glutamatergic neurons in the ventral tegmental area, substantia nigra and pedunculopontine tegmental nucleus express vesicular glutamate transporter 2 in the rat brain. J Comp Neurol (2006) 498:581–92. doi:10.1002/cne.20504

49. Yamasuchi T, Shen W, Morales M. Glutamatergic neurons are present in the ventral tegmental area. Eur J Neurosci (2007) 25:106–18. doi:10.1111/j.1460-9558.2006.05263.x

50. Yamasuchi T, Wang HL, Li X, Ng TH, Morales M. Mesocorticolimbic glutamatergic pathway. J Neurosci (2011) 31:8476–90. doi:10.1523/JNEUROSCI.1159-11.2011

51. Gorelova N, Mulholland PJ, Chandler LJ, Seannik JK. The glutamatergic component of the mesocortical pathway emanating from different subregions of the ventral tegmental area. J Neurosci (2011) 31:2227–36. doi:10.1523/jneurosci.3390-10.107

52. Wang HL, Qi J, Zhang S, Wang H, Morales M. Rewarding effects of optical stimulation of ventral tegmental area glutamatergic neurons. J Neurosci (2015) 35:15948–54. doi:10.1523/JNEUROSCI.3428-15.2015

53. Chuhma N, Zhang H, Masson J, Zhuang X, Sulzer D, Hen R, et al. Dopamine neurons mediate a fast excitatory signal via their glutamatergic synapses. J Neurosci (2004) 24:972–81. doi:10.1523/JNEUROSCI.4317-03.2004

54. Chuhma N, Choi WY, Mingote S, Rayport S. Dopamine neuron glutamate cotransmission: frequency-dependent modulation in the mesocorticolimbic pathway. Neuroscience (2009) 164:1068–83. doi:10.1016/j. neuroscience.2009.08.057

55. Snider GD, Hnasko TS, Britt JP, Edwards RH, Bonci A. Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate. J Neurosci (2010) 30:8229–33. doi:10.1523/JNEUROSCI.1754-10.2010

56. Trecuapella F, Patel IC, Xenias H, English D, Tadros I, Shah F, et al. Glutamatergic signaling by mesolimbic dopamine neurons in the nucleus accumbens. J Neurosci (2010) 30:7105–10. doi:10.1523/JNEUROSCI.0265-10.2010

57. Chuhma N, Mingote S, Moore H, Rayport S. Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron (2014) 81:901–12. doi:10.1016/j.neuron.2013.12.027

58. Zhang S, Qi J, Li X, Wang HL, Britt JP, Hoffman AF, et al. Dopaminergic and glutamatergic microdomains in a subset of rodent mesoaccumbens axons. Nat Neurosci (2015) 18:386–92. doi:10.1038/nn.3945

59. Tsai HC, Zhang F, Adamantidis A, Stuber GD, Bonci A, de Lecca L, et al. Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. Science (2009) 324:1080–4. doi:10.1126/science.1168878
80. Ilango A, Kesner AJ, Keller KL, Stuber GD, Bonci A, Ikemoto S. Similar roles of substantia nigra and ventral tegmental dopamine neurons in reward and aversion. *J Neurosci* (2014) 34:1817–22. doi:10.1523/JNEUROSCI.2703-13.2014

81. Adamantidis AR, Tsai HC, Boutrel B, Zhang F, Stuber GD, Budigyn FA, et al. Optogenetic interrogation of dopaminergic modulation of the multiple phases of reward-seeking behavior. *J Neurosci* (2011) 31:10829–35. doi:10.1523/JNEUROSCI.2246-11.2011

82. Steinberg EE, Keiflin R, Boivin JR, Witten IB, Deisseroth K, Janak PH. A causal link between prediction errors, dopamine neurons and learning. *Nat Neurosci* (2013) 16:966–73. doi:10.1038/nn.3413

83. Ilango A, Kesner AJ, Broker CJ, Wang DV, Ikemoto S. Phasic excitation of ventral tegmental dopamine neurons potentiates the initiation of conditioned approach behavior: parametric and reinforcement-schedule analyses. *Front Behav Neurosci* (2014) 8:155. doi:10.3389/fnbeh.2014.00155

84. Pascoli V, Terrier J, Hiver A, Luscher C. Sufficiency of mesolimbic dopamine neuron stimulation for the progression to addiction. *Neuron* (2015) 88:1054–66. doi:10.1016/j.neuron.2015.10.017

85. Geisler S, Derct C, Veh RW, Zahm DS. Glutamatergic afferents of the ventral tegmental area in the rat. *J Neurosci* (2007) 27:5730–43. doi:10.1523/JNEUROSCI.0012-07.2007

86. Ichou TC, Fields HL, Baxter MG, Saper CB, Holland PC. The rostromedial tegmental nucleus (RMTg), a GABAergic afferent to midbrain dopamine neurons, encodes aversive stimuli and inhibits motor responses. *Neuron* (2009) 61:786–806. doi:10.1016/j.neuron.2009.02.001

87. Watabe-Uchida M, Zhu L, Ogawa SK, Vamanrao A, Uchida N. Whole-brain mapping of direct inputs to midbrain dopamine neurons. *Neuron* (2012) 74:858–73. doi:10.1016/j.neuron.2012.03.017

88. Kauffman J, Veinante P, Pawlowski SA, Freund-Mercier MJ, Barrot M. Afferents to the GABAergic tail of the ventral tegmental area in the rat. *Proc Natl Acad Sci U S A* 2005.1143–64. doi:10.1073/pnas.2008.09.038

89. Hjelmstad GO, Xia Y, Margolis EB, Fields HL. Opioid modulation of ventral pallidal afferents to ventral tegmental area afferent neurons. *J Neurosci* (2013) 33:6454–9. doi:10.1523/JNEUROSCI.0178-13.2013

90. Floresco SB, West AR, Ash B, Moore H, Grace AA. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. *Nat Neurosci* (2003) 6:968–73. doi:10.1038/nn1103

91. Jhou TC, Fields HL, Barrot M, Veinante P, Freund-Mercier MJ, Barrot M. Ventral pallidal injections of a mu-antagonist block the development of behavioral sensitization to systemic morphine. *Synapse* (2000) 38:61–70. doi:10.1002/1098-2396(200010)38:1–61:AID-SYN7+3.0.CO;2-6

92. Mickiewicz AL, Dallimore JE, Napier TC. The ventral pallidum is critically involved in the development and expression of morphine-induced sensitization. *Neuropsychopharmacology* (2009) 34:874–86. doi:10.1038/npp.2008.111

93. Dallimore JE, Mickiewicz AL, Napier TC. Intra-pallidal glutamate antagonists block expression of morphine-induced place preference. *Behav Neurosci* (2006) 120:1103–14. doi:10.1037/0735-7044.120.5.1103

94. Rademacher DJ, Kovacs B, Shen F, Napier TC, Meredith GE. The neural substrates of amphetamine conditioned place preference: implications for the formation of conditioned stimulus-reward association. *Eur J Neurosci* (2006) 24:2089–97. doi:10.1111/j.1460-9568.2006.05066.x

95. Robledo P, Koob GF. Two discrete nucleus accumbens projection areas differentially mediate cocaine self-administration in the rat. *Behav Brain Res* (1993) 55:159–66. doi:10.1016/0166-4328(93)90112-4

96. Tang XC, McFarland K, Cagle S, Kalivas PW. Cocaine-induced reinstatement requires endogenous stimulation of mu-opioid receptors in the ventral pallidum. *J Neurosci* (2005) 25:4512–20. doi:10.1523/JNEUROSCI.0685-05.2005

97. Mahler SV, Vazey EM, Beckley JT, Keister CR, Gilmcilkey EM, Kauffman J, et al. Designer receptors show role for ventral pallidum input to ventral tegmental area in cocaine seeking. *Nat Neurosci* (2014) 17:577–85. doi:10.1038/nn.3664

98. Walker DL, Davis M. Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. *J Neurosci* (1997) 17:9375–83.

99. Cecchi M, Khoshbouei H, Javors M, Morilak DA. Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. *Neuroscience* (2002) 112:13–21. doi:10.1016/S0306-4522(02)00682-3

100. Fendt M, Endres T, Apfelbach R. Temporary inactivation of the bed nucleus of the stria terminalis disrupt corticosterone and freezing responses elicited by a contextual but not by a specific cue-conditioned fear stimulus. *Neuroscience* (2004) 128:7–14. doi:10.1016/j.neuroscience.2004.06.015

101. Deyama S, Katayama T, Ohno A, Nakagawa T, Kaneko S, Yamaguchi T, et al. Activation of the beta-adrenoceptor-protein kinase A signaling pathway within the ventral bed nucleus of the stria terminalis mediates the negative affective component of pain in rats. *J Neurosci* (2008) 28:7726–36. doi:10.1523/JNEUROSCI.1480-08.2008

102. Walker DL, Davis M. Role of the extended amygdala in short-duration versus sustained fear: a tribute to Dr. Lennart Heimer. *Brain Struct Funct* (2008) 213:29–42. doi:10.1007/s00429-008-0183-3
120. Walker DL, Miles LA, Davis M. Selective participation of the bed nucleus of the stria terminals and CRF in sustained anxiety-like versus phasic fear-like responses. Prog Neuro-psychopharmacol Biol Psychiatry (2009) 33:1291–308. doi:10.1016/j.pnpb.2009.06.022

121. Herman JP, Cullinan WE. Neurocircuity of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci (1997) 20:78–84. doi:10.1016/S0166-2236(96)10069-2

122. Jalabert M, Aston-Jones G, Herzog E, Manzoni O, Georges F. Role of the bed nucleus of the stria terminalis in the control of ventral tegmental area dopamine neurons. Prog Neuro-psychopharmacol Biol Psychiatry (2009) 33:1336–46. doi:10.1016/j.pnpb.2009.07.010

123. Poulin JF, Arbour D, Lafort S, Drolet G. Neuroanatomical characterization of endogenous opioids in the bed nucleus of the stria terminalis. Prog Neuro-psychopharmacol Biol Psychiatry (2009) 33:1356–65. doi:10.1016/j.pnpb.2009.06.021

124. Kash TL, Pleil KE, Marcinkiewcz CA, Lowery-Gianta EG, Crowley N, Mazzone C, et al. Neuropeptide regulation of signaling and behavior in the BNST. Mol Cells (2015) 38:1–13. doi:10.14348/molcells.2015.2261

125. Georges F, Aston-Jones G. Potentiation of midbrain dopamine neurons by the bed nucleus of the stria terminalis. J Neurosci (2001) 21:RC160.

126. Georges F, Aston-Jones G. Activation of ventral tegmental area cell bodies by the bed nucleus of the stria terminalis: a novel excitatory amino acid input to midbrain dopamine neurons. J Neurosci (2002) 22:5173–87.

127. Wanat MJ, Bonci A, Phillips PE. CRF acts in the midbrain to attenuate accumbans dopamine release to rewards but not their predictors. Nat Neurosci (2013) 16:383–5. doi:10.1038/nn.3335

128. Kudo T, Uchigashima M, Miyazaki T, Konno K, Yamazaki M, Yanagawa Y, et al. Three types of neurochemical projection from the bed nucleus of the stria terminalis to the ventral striatal area in adult mice. J Neurosci (2012) 32:18035–46. doi:10.1523/JNEUROSCI.0414-12.2012

129. Jennings JH, Sparta DR, Stamatakis AM, Ung RL, Pleil KE, Kash TL, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci (2003) 23:3106–11.

130. Nairn CT, Pathak D, Maldonado R, Pertiscanski E, Tancik M, Shih Y, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci (2015) 35:488–496. doi:10.1523/JNEUROSCI.2761-05.2006

131. Harris GC, Wimmer M, Randall-Thompson JF, Aston-Jones G. Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. Behav Brain Res (2007) 183:43–51. doi:10.1016/j.bbr.2007.05.025

132. Georgescu D, Zacharias V, Barrot M, Mieda M, Willle TJ, Eisch AJ, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci (2003) 23:3106–11.

133. Bogdahn SL, Taha SA, Sarti F, Fields HL, Bonci A, Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. J Neurosci (2006) 26:459–601. doi:10.1523/JNEUROSCI.0042-06.2006

134. Muschamp JW, Holland JA, Thompson JL, Voren G, Hassinger LC, Onvani S, et al. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci U S A (2014) 111:E1648–55. doi:10.1073/pnas.1315542111

135. James MH, Charnley JL, Levi EM, Jones E, Yeoh JW, Smith DW, et al. Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical for regulating cue-induced reinstatement of cocaine-seeking. Int J Neuropharmacol (2011) 14:684–90. doi:10.1016/j.biopsych.2010.11.023

136. Inglis WL, Olmstead MC, Robbins TW. Pedunculopontine tegmental nucleus lesions impair stimulus – reward learning in autoshaping and conditioned reinforcement paradigms. Behav Neurosci (2000) 114:285–94. doi:10.1037/0735-7044.114.2.285

137. Inglis WL, Olmstead MC, Robbins TW. Selective deficits in attentional performance on the 5-choice serial reaction time task following pedunculopontine tegmental nucleus lesions. Brain Research (2001) 923:117–31. doi:10.1016/S0006-8993(01)00818-4

138. Yeomans JS. Muscarinic receptors in brain stem and mesopontine cholinergic arousal function. Handb Exp Pharmacol (2012):243–59. doi:10.1007/978-3-642-32374-9_11

139. Steidl S, Vevrka K. Optogenetic excitation of LDTg axons in the VTA re-enforces operant responding in rats. Brain Res (2015) 1614:86–93. doi:10.1016/j.brainres.2015.04.021

140. Oakman SA, Faris PL, Kerr PE, Cozzari C, Hartman BK. Distribution of pontomesencephalic cholinergic neurons projecting to substantia nigra differs significantly from those projecting to ventral tegmental area. J Neurosci (1995) 15:5859–69.

141. Wang HL, Morales M. Pedunculopontine and laterodorsal tegmental nucleus contain distinct populations of cholinergic, glutamatergic and GABAergic neurons in the rat. Eur J Neurosci (2009) 29:340–58. doi:10.1111/j.1460-9568.2008.06576.x

142. Omelchenko N, Sesack SR. Laterodorsal tegmental projections to identified cell populations in the rat ventral tegmental area. J Comp Neurol (2005) 483:217–35. doi:10.1002/cne.20417
Oliva and Wanat

158. Lodge DJ, Grace AA. The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons. Proc Natl Acad Sci U S A (2006) 103:5167–72. doi:10.1073/pnas.0510715103.

159. Shinozaki F, Kihara Y, Ide S, Minami M, Kaneda K. Critical role of cholinergic transmission from the laterodorsal tegmental nucleus to the ventral tegmental area in cocaine-induced place preference. Neuropharmacology (2014) 79:573–9. doi:10.1016/j.neuropharm.2014.01.019.

160. Schmidt HD, Famous KR, Pierce RC. The limbic circuitry underlying cocaine seeking encompasses the PPT/LDT. Eur J Neurosci (2009) 30:1338–69. doi:10.1111/j.1460-9568.2009.06094.x.

161. Steidl S, Cardiff KM, Wise RA. Increased latencies to initiate cocaine self-administration following laterodorsal tegmental nucleus lesions. Behav Brain Res (2015) 287:82–8. doi:10.1016/j.bbr.2015.02.049.

162. Pan WX, Hyland BL. Pedunculopontine tegmental nucleus controls conditioned responses of midbrain dopamine neurons in behaving rats. J Neurosci (2005) 25:4725–32. doi:10.1523/JNEUROSCI.0277-05.2005.

163. Good CH, Lupica CR. Properties of distinct ventral tegmental area synapses activated via pedunculopontine or ventral tegmental area stimulation in vitro. J Physiol (2009) 587:1233–47. doi:10.1113/jphysiol.2008.161494.

164. Bechara A, van der Kooy D. Lesions of the ventralpedunculopontine tegmental nucleus: effects on the locomotor activity induced by morphine and amphetamine. Pharmacol Biochem Behav (1992) 42:9–18. doi:10.1016/0091-3057(92)90458-L.

165. Olmstead MC, Franklin KR. Effects of pedunculopontine tegmental nucleus lesions on morphine-induced conditioned place preference and analgesia in the formalin test. Neurscience (1993) 57:411–8. doi:10.1016/0366-4522(93)90072-N.

166. Olmstead MC, Munn EM, Franklin KR, Wise RA. Effects of pedunculopontine tegmental nucleus lesions on responding for intravenous heroin under different schedules of reinforcement. J Neurosci (1998) 18:5035–44.

167. Steidl S, Wang H, Wise RA. Lesions of cholinergic pedunculopontine tegmental nucleus neurons fail to affect cocaine or heroin self-administration or conditioned place preference in rats. PLoS One (2014) 9:e84412. doi:10.1371/journal.pone.0084412.

168. Charara A, Parent A. Chemoarchitecture of the primate dorsal raphe nucleus. J Chem Neuroanat (1998) 15:111–7. doi:10.1016/S0891-0618(98)00036-2.

169. Dougalis AG, Matthews GA, Bishop MW, Brischoff C, Kobayashi K, Ungless MA. Functional properties of dopamine neurons and co-expression of vasoactive intestinal polypeptide in the dorsal raphe nucleus and ventro-lateral periaqueductal grey. Eur J Neurosci (2012) 36:3322–32. doi:10.1111/j.1460-9568.2012.08255.x.

170. Lowry CA, Hale MW, Evans AK, Heerken J, Staub DR, Gasser PJ, et al. Serotoninergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann N Y Acad Sci (2008) 1148:86–94. doi:10.1196/annals.1410.004.

171. Liu Z, Zhou J, Li Y, Hu F, Ma M, et al. Dorsal raphe neurons signal reward through 5-HT1F and glutamate. Neuron (2014) 81:1360–74. doi:10.1016/j.neuron.2014.02.010.

172. Pessa M, Jiang ZG, North RA, Johnson SW. Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res (1994) 654:324–30. doi:10.1016/0006-8993(94)90495-2.

173. Guan XM, McBride WJ. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull (1989) 23:541–7. doi:10.1016/0361-9204(89)90198-6.

174. Muller CP, Homberg JR. The role of serotonin in drug use and addiction. Behav Brain Res (2015) 277:146–92. doi:10.1016/j.bbr.2014.04.007.

175. Qi, Zhang W, Wang HL, Wang H, de Jesus Acves Buendia J, Hoffman AF, et al. A glutamatergic reward input from the dorsal raphe to ventral tegmental area dopamine neurons. Nat Commun (2014) 5:5390. doi:10.1038/ncomms5390.

176. McDevitt RA, Tiran-Cappello A, Shen H, Balderas I, Britt JP, Marino RA, et al. Serotonergic versus nonserotonergic dorsal raphe projection neurons: differential participation in reward circuitry. Cell Rep (2014) 8:1857–69. doi:10.1016/j.celrep.2014.08.037.

177. Rahman S, McBride WJ. Feedback control of mesolimbic somatodendritic dopamine release in rat brain. J Neurochem (2000) 74:684–92. doi:10.1046/j.1471-4159.2000.74684.x.

178. Xia Y, Driscoll JR, Wilbrecht L, Margolis EB, Fields HL, Hjelmstad GO. Nucleus accumbens medium spiny neurons target non-dopaminergic neurons in the ventral tegmental area. J Neurosci (2011) 31:7811–6. doi:10.1523/JNEUROSCI.1504-11.2011.
placebo-controlled trial. Alcohol Alcohol (2011) 46:312–7. doi:10.1093/alca/agr017

222. huth JL, Malte CA, Dietel B, Tell D, Pocock I, Lyons R, et al. A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res (2015) 39:808–17. doi:10.1111/acrr.12703

223. Gessa GL, Serra S, Vaccia G, Carai MA, Colombo G. Supressing effect of the cannabinoid CB1 receptor antagonist, SR14776, on alcohol intake and motivational properties of alcohol in alcohol-prefering S.P rats. Alcohol Alcohol (2005) 40:46–53. doi:10.1093/alca/agh114

224. Cheer JF, Wassum KM, Sommers LA, Heien ML, Ariensen JL, Aragona BJ, et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci (2007) 27:791–5. doi:10.1523/JNEUROSCI.4152-06.2007

225. Topol EL, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 376:517–23. doi:10.1016/S0140-6736(10)60935-X

226. Creed M, Pascoli VJ, Luscher C. Addiction therapy. Refining deep brain stimulation to emulate optogenetic treatment of synaptic pathology. Science (2015) 347:659–64. doi:10.1126/science.1260776

227. Liu HY, Jin J, Tang JS, Sun WX, Jia H, Yang XP, et al. Chronic deep brain stimulation in the rat nucleus accumbens and its effect on morphine reinforcement. Addict Biol (2008) 13:40–6. doi:10.1111/j.1369-1600.2007.00988.x

228. Guo L, Zhou H, Wang R, Xu J, Zhou W, Zhang F; et al. DBS of nucleus accumbens on heroin seeking behaviors in self-administering rats. Drug Alcohol Depend (2013) 129:70–81. doi:10.1016/j.drugalcdep.2012.09.012

229. Vassoler FM, Schmidt HD, Gerard ME, Famous KR, Ciraulo DA, Kornetsky C, et al. Deep brain stimulation of the nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug seeking in rats. J Neurosci (2008) 28:8735–9. doi:10.1523/JNEUROSCI.5277-07.2008

230. Guercio LA, Schmidt HD, Pierce RC. Deep brain stimulation of the nucleus accumbens shell attenuates cue-induced reinstatement of both cocaine and sucrose seeking in rats. Behav Brain Res (2015) 281:125–30. doi:10.1016/j.bbr.2014.12.025

231. Hamilton J, Lee J, Canales JJ. Chronic unilateral stimulation of the nucleus accumbens at high or low frequencies attenuates relapse to cocaine seeking in an animal model. Brain Stimul (2015) 8:57–63. doi:10.1016/j.brs.2014.09.018

232. Friedman A, Lax E, Dikshtein Y, Abraham L, Flaumenhaft Y, Sudai E, et al. Electrical stimulation of the lateral habenula produces enduring inhibitory effect on cocaine seeking behavior. Neuropharmacology (2010) 59:452–9. doi:10.1016/j.neuropharm.2010.06.008

233. Zhou H, Xu J, Jiang J. Deep brain stimulation of nucleus accumbens on heroin-seeking behaviors: a case report. Biol Psychiatry (2011) 69:e41–2. doi:10.1016/j.biopsych.2011.02.012

234. Valencia-Alfonso CE, Luigjes J, Smolders R, Cohen MX, Levar N, Mazaheri A, et al. Effective deep brain stimulation in heroin addiction: a case report with complementary intracranial electroencephalogram. Biol Psychiatry (2012) 71:e35–7. doi:10.1016/j.biopsych.2011.12.013

235. Terraneo A, Leggio L, Saladini M, Ermani M, Bonci A, Galli L. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: a pilot study. Eur Neuropsychopharmacol (2016) 26(1):37–44. doi:10.1016/j.euroneuro.2015.11.011

236. Enokibara M, Treviolar P, Shiosawa P, Cordeiro Q. Establishing an effective TMS protocol for craving in substance addiction: is it possible? Am J Addict (2016) 25:28–30. doi:10.1111/ajad.12309

237. Britt JP, Bonci A. Optogenetic interrogations of the neural circuits underpinning addiction. Curr Opin Neurobiol (2013) 23:539–45. doi:10.1016/j.conb.2013.01.010

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.